ZFAS1

Summary

ZFAS1 (ZNFX1 antisense RNA 1, HGNC:33101) is a long non-coding RNA gene on chromosome 20q13.13.

This gene represents a snoRNA host gene that produces a non-coding RNA. Increased expression or amplification of this locus is associated with cancer progression and metastasis. This transcript regulates expression of genes involved in differentiation. It may act a molecular sponge for microRNAs. Alternatively spliced transcript variants have been observed.

Source: NCBI Gene 441951 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33101
Approved symbol	ZFAS1
Name	ZNFX1 antisense RNA 1
Location	20q13.13
Locus type	RNA, long non-coding
Status	Approved
Aliases	HSUP1, HSUP2
Ensembl gene	ENSG00000177410
Ensembl biotype	lncRNA
Entrez	441951
RNAcentral	URS000045E7E2 — lncRNA, 1008 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 47 — 46 lncRNA, 1 retained_intron

ENST00000326677, ENST00000371743, ENST00000417721, ENST00000428008, ENST00000441722, ENST00000450535, ENST00000458653, ENST00000618800, ENST00000620594, ENST00000623640, ENST00000652916, ENST00000659056, ENST00000663883, ENST00000667889, ENST00000836970, ENST00000836971, ENST00000836972, ENST00000836973, ENST00000836974, ENST00000836975, ENST00000836976, ENST00000836977, ENST00000836978, ENST00000836979, ENST00000836980, ENST00000836981, ENST00000836982, ENST00000836983, ENST00000836984, ENST00000836985, ENST00000836986, ENST00000836987, ENST00000836988, ENST00000836989, ENST00000836990, ENST00000836991, ENST00000836992, ENST00000836993, ENST00000836994, ENST00000836995, ENST00000836996, ENST00000836997, ENST00000836998, ENST00000836999, ENST00000837000, ENST00000837001, ENST00000837002

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000326677 — 4 exons

Exon	Start	End
ENSE00001455994	49280485	49280570
ENSE00001787919	49279104	49279208
ENSE00004256975	49289045	49289261
ENSE00004257002	49278602	49278738

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 99.68.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2829 / max 27.2690, expressed in 118 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
185159	289.7515	1826
185160	0.7526	442
185162	0.7224	367
185161	0.2829	118

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper arm skin	UBERON:0004263	99.68	gold quality
cartilage tissue	UBERON:0002418	99.67	gold quality
cortical plate	UBERON:0005343	99.41	gold quality
ganglionic eminence	UBERON:0004023	99.39	gold quality
ileal mucosa	UBERON:0000331	99.34	gold quality
left ovary	UBERON:0002119	99.25	gold quality
tibialis anterior	UBERON:0001385	99.16	gold quality
calcaneal tendon	UBERON:0003701	99.00	gold quality
right ovary	UBERON:0002118	98.96	gold quality
ovary	UBERON:0000992	98.95	gold quality
skin of abdomen	UBERON:0001416	98.94	gold quality
monocyte	CL:0000576	98.92	gold quality
leukocyte	CL:0000738	98.91	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	98.89	gold quality
skin of leg	UBERON:0001511	98.86	gold quality
upper leg skin	UBERON:0004262	98.82	gold quality
zone of skin	UBERON:0000014	98.81	gold quality
trachea	UBERON:0003126	98.80	gold quality
nipple	UBERON:0002030	98.74	gold quality
ventricular zone	UBERON:0003053	98.72	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	98.71	gold quality
mucosa of stomach	UBERON:0001199	98.65	gold quality
right uterine tube	UBERON:0001302	98.64	gold quality
skin of hip	UBERON:0001554	98.63	gold quality
spinal cord	UBERON:0002240	98.60	gold quality
endocervix	UBERON:0000458	98.59	gold quality
pericardium	UBERON:0002407	98.58	gold quality
right lung	UBERON:0002167	98.57	gold quality
epithelium of mammary gland	UBERON:0003244	98.56	gold quality
mammary duct	UBERON:0001765	98.55	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-10662	no	3264.68
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• ZFAS1 is highly expressed in the mammary gland and is down-regulated in breast tumors compared to normal tissue (PMID:21460236)
• Up-regulation of ZFAS1 is correlated with poor prognosis and metastasis in hepatocellular carcinoma patients. (PMID:26069248)
• ata suggest that long non-coding RNA ZFAS1 may function as oncogene via destabilization of tumor suppressor protein p53 (p53) and through cyclin-dependent kinase 1 (CDK1)/cyclin B1 complex leading to cell cycle progression and inhibition of apoptosis. (PMID:26506418)
• ZFAS1 over-expression confers an oncogenic function in gastric cancer and this function is partly dependent on repressing KLF2 and NKD2 (PMID:27246976)
• The expression of ZFAS1 is positively correlated with TNM stage and appears to be a new prognostic factor in colorectal cancer. ZFAS1 promptes cell migration, invasive and metastasis ability of colorectal cancer cells. (PMID:27461828)
• Taken together, our results suggested that ZFAS1 was up-regulated in both tissues and plasmas of gastric cancer patients, and may be involved in regulation of EMT in gastric cancer progression. (PMID:27654478)
• ZFAS1 may function as an oncogene by modulating ZEB1 to induce EMT. Manipulation of ZFAS1 level may be a novel approach to suppress colonic cancer progression. (PMID:27862275)
• ZFAS1 could exhibit a tumor oncogenic role in glioma progression. (PMID:28081466)
• High ZFAS1 expression is associated with chemotherapy resistance in ovarian cancer. (PMID:28099946)
• ZFAS1 could be delivered by exosomes to promote gastric cancer (GC) progression, which suggests that ZFAS1 may serve as a potential diagnostic and prognostic biomarker for GC. (PMID:28285404)
• Taken together, our data identified that zinc finger antisense 1 might act as a valuable prognostic biomarker and potential therapeutic target for glioma (PMID:28349823)
• we identified MIR155HG and TERC to be transcriptionally downregulated by PRDM1 in two PRDM1-null NK-cell lines when it is ectopically expressed. These findings suggest that ZFAS1 and other dysregulated long non-coding RNAs may be involved in natural killer/T-cell lymphoma pathobiology through regulation of cancer-related genes, and loss-of-PRDM1 expression in natural killer/T-cell lymphomas tumorigenesis (PMID:28468592)
• ZFAS1 promotes cell migration and invasion through miR-27a in RA-FLS, suggesting that ZFAS1 may be an effective therapeutic target for RA patients. (PMID:28721682)
• The study suggested that ZFAS1 could act as an oncogene in colorectal cancer tumorigenesis, and discovered the functional regulatory pathway of ZFAS1 sponging miR-484. (PMID:29179614)
• Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/beta-catenin signaling in gastric cancer cells (PMID:29424266)
• These findings indicated that the lncRNA ZFAS1 may be a tumor suppressor in breast cancer, and thus, may serve as a potential therapeutic target for patients with breast cancer. (PMID:29532866)
• The levels of plasma ZFAS1 in hepatocellular carcinoma were significantly higher than those in healthy controls (P<0.001), and in patients with cirrhosis and hepatitis B (P<0.001), and was positively associated with serum alpha-fetoprotein (AFP). (PMID:29559565)
• ZFAS1 could serve as an oncogene in the tumorigenesis of bladder cancer, and discovered the functional regulatory network of ZFAS1 sponging miR-329. (PMID:29653362)
• The experiments in vitro suggested that knockdown of ZFAS1 repressed bladder cancer cell proliferation via up-regulating KLF2 and NKD2 expression, and inhibited cell migration and invasion via down-regulating ZEB1 and ZEB2 expression. (PMID:29678899)
• ZFAS1 provides a potential therapeutic target for OA treatment. (PMID:29703568)
• ZFAS1 was overexpressed in nasopharyngeal carcinoma and was significantly related to tumor size, lymph node metastasis and poor prognosis of NPC. ZFAS1 could promote NPC by activating Wnt/beta-catenin pathway. (PMID:29917194)
• ZFAS1 expression was found to be increased in colorectal cancer cells and tissues, and was activated by transcription factor SP1. ZFAS1, acting as a miR-150-5p sponge, promoted tumor growth, metastasis, and angiogenesis in colorectal cancer. (PMID:30250022)
• ZFAS1 has been shown to have oncogenic function in tumourigenesis and tumour progression and may act as a potential cancer- specific molecular biomarker in the general diagnosis, prognosis, and treatment of cancer. (PMID:30288832)
• Collectively, our data showed that ZFAS1 contributed to the development of AML by sequestering miR-150 from Myb or Sp1, elucidating the central roles of ZFAS1/miR-150/Myb and ZFAS1/miR-150/Sp1 pathways in the tumorigenesis of AML and deepening our understanding on the etiology of leukemia. (PMID:30502345)
• The lncRNA ZFAS1 was upregulated in cervical cancer tissues, and its high expression indicated a poor prognosis. Silencing ZFAS1 may inhibit cell proliferation, migration and invasion and enhance cisplatin chemosensitivity. (PMID:30738960)
• LncRNA ZNFX1-AS1 is significantly upregulated in colorectal cancer, and promotes colorectal cancer cell proliferation, invasion, tumorigenesis, and metastasis by acting as a ceRNA of miR-144 to regulate the expression of EZH2. (PMID:30770796)
• ZFAS1 promotes growth and metastasis of ccRCC via targeting miR-10a/SKA1 pathway. (PMID:30841471)
• Knockdown of ZFAS1 decreased proliferation, increased apoptosis, decreased migration and invasion, and reduced epithelial-mesenchymal transition potential in melanoma cells. (PMID:30889053)
• demonstrated a critical role of miR-200b in gastric cancer, and ZFAS1 can promote malignant progression through regulating miR-200b mediated Wnt/beta-catenin signaling (PMID:30999814)
• ZFAS1 displays oncogenic properties, regulates important processes associated with EMT, cancer-initiating cells, and metastases, and might affect patients’ clinical outcomes. ZFAS1 likely regulates the cell phenotype through miR-150-5p and its downstream targets. (PMID:31010087)
• Functional validation showed knockdown of ZFAS1 suppressed cell proliferation and cell cycle in thyroid cancer cells. Bioinformatics analysis showed ZFAS1 was associated with translation, rRNA processing, intra-Golgi vesicle-mediated transport, ribosome, and ubiquitin-mediated proteolysis. (PMID:31012438)
• Long non-coding RNA ZFAS1 regulates NOB1 expression through interacting with miR-646 and promotes tumorigenesis in osteosarcoma. (PMID:31081072)
• Long noncoding RNA ZFAS1 promotes cell proliferation and tumor growth by upregulating LIN28 in cervical carcinoma. (PMID:31142096)
• Knockdown of ZFAS1 and miR-432-5p overexpression inhibited cell viability and enhanced the chemosensitivity of glioma cells to cisplatin. MiR-432-5p was a direct target of ZFAS1 in glioma cells. (PMID:31246330)
• Study indicated that ZFAS1 directly targeted miR-7-5p, and knockdown of it could inhibit tumor growth, migration, invasion, and induce apoptosis in CRC. (PMID:31295229)
• knockdown of ZFAS1 or addition of miR-135a inhibited cell proliferation, migration and invasion but promoted apoptosis in Nasopharyngeal carcinoma cells (PMID:31307201)
• High ZFAS1 expression is associated with nasopharyngeal carcinoma via the PI3K/AKT pathway. (PMID:31403940)
• The long noncoding RNA ZFAS1 promotes the progression of glioma by regulating the miR-150-5p/PLP2 axis. (PMID:31535380)
• Up-regulation of ZFAS1 indicates dismal prognosis for cholangiocarcinoma and promotes proliferation and metastasis by modulating USF1 via miR-296-5p. (PMID:31565837)
• Study highlights that exosomal ZFAS1 promotes the proliferation, migration and invasion of ESCC cells and inhibits their apoptosis by upregulating STAT3 and downregulating miR-124, thereby resulting in the development of tumorigenesis of ESCC. (PMID:31775815)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.